- Trials with a EudraCT protocol (107)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
107 result(s) found for: Wet AMD AND Age-Related Macular Degeneration.
Displaying page 2 of 6.
EudraCT Number: 2007-001281-33 | Sponsor Protocol Number: RGHT000449 | Start Date*: 2007-07-09 | |||||||||||
Sponsor Name:Belfast Health and Social Care Trust [...] | |||||||||||||
Full Title: A randomised control trial of alternative treatments to Inhibit VEGf in Age-related choroidal Neovascularisation(IVAN) | |||||||||||||
Medical condition: Choroidal neovascularisation in age related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2009-016926-15 | Sponsor Protocol Number: OFT-09-01 | Start Date*: 2010-03-11 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI | |||||||||||||
Full Title: Intravitreal Bevacizumab associated with epiretinal brachitherapy as a treatment for Coroidal Neovascularization (CNV) secondary to exudative Age Related Macular Degeneration (AMD) | |||||||||||||
Medical condition: exudative Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001961-20 | Sponsor Protocol Number: FYB201-C2015-01-P3 | Start Date*: 2015-11-24 | ||||||||||||||||
Sponsor Name:Bioeq GmbH | ||||||||||||||||||
Full Title: Efficacy and safety of the biosimilar ranibizumab FYB201 in comparison to Lucentis in patients with neovascular age-related macular degeneration (COLUMBUS-AMD) | ||||||||||||||||||
Medical condition: Subfoveal neovascular age-related macular degeneration | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: CZ (Completed) AT (Completed) DE (Completed) HU (Completed) ES (Completed) FR (Completed) GB (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2005-005290-30 | Sponsor Protocol Number: TCA-05-01 | Start Date*: 2006-10-18 | |||||||||||
Sponsor Name:Department of Ophthalmology, Semmelweis University | |||||||||||||
Full Title: A Non- randomized, Single-Center, Open Label Case Series Study of Intravitreal Triamcinolone Acetate Injections (IVTA) Used as Adjunctive to Verteporfin Photodynamic Therapy (PDT) in the Treatment ... | |||||||||||||
Medical condition: Age- related macular degeneration with predominantly classic subfoveal choroidal neovascularisation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-013062-11 | Sponsor Protocol Number: AR-OCUL-1 | Start Date*: 2007-03-29 | |||||||||||
Sponsor Name:AZIENDA USL 8 AREZZO | |||||||||||||
Full Title: BEVACIZUMAB COMBINED WITH PDT, VERSUS RANIBIZUMAB AND PEGAPTANIB BOTH COMBINED WITH PDT FOR NEOVACULAR AGE RELATED MACULAR DEGENERATION CLINICAL TRIAL | |||||||||||||
Medical condition: Neovascular Age Related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004367-57 | Sponsor Protocol Number: | Start Date*: 2008-05-14 | |||||||||||
Sponsor Name:Department of Ophthalmology, Medical University of Graz | |||||||||||||
Full Title: Treatment of retinal angiomatous proliferation lesions due to age-related macular degeneration with ranibizumab (Lucentis®) and photodynamic therapy with verteporfin (Visudyne®) | |||||||||||||
Medical condition: Subtype of neovascular age-related macular degeneration, so called retinal angiomatous proliferation or RAP. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-000519-42 | Sponsor Protocol Number: OPH1008 | Start Date*: 2015-10-26 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: Role of multimodal imaging in the evaluation of anatomic alterations in neovascular Age-Related Macular Degeneration (AMD) subjects: 18 month Phase 2a open label study of Fovista® (anti-PDGF therap... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to Age-Related Macular Degeneration (AMD) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-006358-86 | Sponsor Protocol Number: ATG003-201 | Start Date*: 2007-04-27 | |||||||||||
Sponsor Name:CoMentis, Inc., USA | |||||||||||||
Full Title: A PHASE II RANDOMIZED, DOUBLE-MASKED, STUDY COMPARING THE SAFETY AND EFFICACY OF ATG003 (MECAMYLAMINE HCL) 1.0% and 0.3% OPHTHALMIC SOLUTIONS TO PLACEBO IN PATIENTS WITH NEOVASCULAR ("WET") AGE-REL... | |||||||||||||
Medical condition: Neovascular ("wet") Age-related Macular Degeneration (NV- AMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-006014-18 | Sponsor Protocol Number: 1419 | Start Date*: 2005-12-15 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: Macular structure and function after intravitreal injection of bevacizumab for wet macular degeneration a interventional study. | |||||||||||||
Medical condition: Macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-004523-16 | Sponsor Protocol Number: GR42691 | Start Date*: 2021-04-12 | |||||||||||
Sponsor Name:F.Hoffmann La-Roche Ltd | |||||||||||||
Full Title: A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | |||||||||||||
Medical condition: Neovascular age-related macular degeneration (nAMD) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) DE (Completed) AT (Completed) DK (Completed) HU (Completed) PL (Completed) NL (Completed) IT (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-003017-18 | Sponsor Protocol Number: OPH1003 | Start Date*: 2013-11-21 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Prematurely Ended) DE (Completed) ES (Prematurely Ended) DK (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002997-33 | Sponsor Protocol Number: OPH1002A | Start Date*: 2014-02-11 | ||||||||||||||||
Sponsor Name:OPHTHOTECH CORPORATION | ||||||||||||||||||
Full Title: A phase 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of Fovista™ (anti PDGF-b pegylated aptamer) administered in combination w... | ||||||||||||||||||
Medical condition: Subfoveal choroidal neovascularization secondary to age-related macular degeneration (AMD). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) EE (Prematurely Ended) SK (Prematurely Ended) BE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-001492-37 | Sponsor Protocol Number: Z-AMD | Start Date*: 2019-11-01 | |||||||||||
Sponsor Name:Oslo University Hospital | |||||||||||||
Full Title: Zoledronic acid as adjuvant therapy in neovascular Age-related Macular Degeneration (The Z-AMD study): a randomized controlled pilot study | |||||||||||||
Medical condition: Neovascular Age-related Macular Degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-005684-26 | Sponsor Protocol Number: Version_1_10072006 | Start Date*: 2007-09-06 | |||||||||||||||||||||
Sponsor Name:Universitätsklinik für Augenheilkunde und Optometrie, AKH Wien | |||||||||||||||||||||||
Full Title: Identification and Quantification of Cytokines in Anti-VEGF Therapy and Genetic Risk Factors in Exsudative Age-related Macular Degeneration | |||||||||||||||||||||||
Medical condition: Exsudative age-related macular degeneration (AMD), cataract, macular pucker | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: AT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-000536-28 | Sponsor Protocol Number: C-10-083 | Start Date*: 2011-09-12 | |||||||||||
Sponsor Name:Alcon Research Ltd. | |||||||||||||
Full Title: Safety and efficacy study with ESBA1008 versus Lucentis for the treatment of exudative age-related macular degeneration | |||||||||||||
Medical condition: wet age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002608-97 | Sponsor Protocol Number: | Start Date*: 2015-09-09 | |||||||||||
Sponsor Name:Belfast Health and Social Care Trust | |||||||||||||
Full Title: Five year observational follow-up of the IVAN trial cohort: a study of function and morphology | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-004844-35 | Sponsor Protocol Number: TG-MV-005 | Start Date*: 2009-07-01 | |||||||||||||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||||||||||||
Full Title: A randomized, sham-injection controlled, double-masked, multicenter trial of microplasmin intravitreal injection for treatment of exudative age-related macular degeneration (AMD). | |||||||||||||||||||||||
Medical condition: Patients with exudative AMD with focal vitreomacular adhesion | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FR (Completed) GB (Completed) DE (Completed) IT (Completed) BE (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000765-20 | Sponsor Protocol Number: ANTIVEGFVEP | Start Date*: 2015-11-27 | |||||||||||||||||||||
Sponsor Name:Kuopion yliopistollinen sairaala/silmätautien poliklinikka | |||||||||||||||||||||||
Full Title: The Effect of Intravitreal Bevacizumab Injections in Patients with Macular Oedema Caused by AMD, CRVO or DME on the Plasticity of Nerves Studied by Visual Evoked Potentials | |||||||||||||||||||||||
Medical condition: Wet age-related macular degeneration, diabetic macular edema, central retinal vein occlusion | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: FI (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-006073-84 | Sponsor Protocol Number: MD7108240 | Start Date*: 2008-02-25 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development | |||||||||||||
Full Title: A double-masked, randomized, parallel-group study to investigate the pharmacodynamics, safety, and systemic pharmacokinetics of pazopanib eye drops, administered for 28 days to adult subjects with ... | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021923-29 | Sponsor Protocol Number: 10032011 | Start Date*: 2011-08-11 | |||||||||||
Sponsor Name:Universitätsklinik für Augenheilkunden und Optometrie, Medizinische Universität Wien | |||||||||||||
Full Title: Management of recurrent or persistent choroidal neovascularization secondary to age-related macular degeneration A prospective, randomized, clinical study | |||||||||||||
Medical condition: Neovascular age-related macular degeneration | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
